share_log

Intelligent Bio Solutions | D: Filing D

Intelligent Bio Solutions | D: Filing D

Intelligent Bio Solutions | D：发行公告
SEC announcement ·  03/22 10:02
Moomoo AI 已提取核心信息
Intelligent Bio Solutions Inc. has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the SEC. The offering, which closed on March 12, 2024, raised a total of $10,100,683 USD. The company, incorporated in Delaware and operating in the healthcare sector, specifically within the 'Other Health Care' category, has not disclosed its revenue range or aggregate net asset value. The securities offered included equity and options, warrants, or other rights to acquire another security. A minimum investment of $10,000 USD was accepted from outside investors, with a total of 8 investors participating in the offering. Sales commissions totaled $910,455 USD, paid to Ladenburg Thalmann & Co. Inc., which also received common stock warrants and reimbursement expenses. No proceeds from the offering are to be used for payments to executive officers, directors, or promoters. Intelligent Bio Solutions' principal place of business is located in New York, New York, with key executives including CEO Harry Simeonidis and CFO Spiro Sakiris.
Intelligent Bio Solutions Inc. has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the SEC. The offering, which closed on March 12, 2024, raised a total of $10,100,683 USD. The company, incorporated in Delaware and operating in the healthcare sector, specifically within the 'Other Health Care' category, has not disclosed its revenue range or aggregate net asset value. The securities offered included equity and options, warrants, or other rights to acquire another security. A minimum investment of $10,000 USD was accepted from outside investors, with a total of 8 investors participating in the offering. Sales commissions totaled $910,455 USD, paid to Ladenburg Thalmann & Co. Inc., which also received common stock warrants and reimbursement expenses. No proceeds from the offering are to be used for payments to executive officers, directors, or promoters. Intelligent Bio Solutions' principal place of business is located in New York, New York, with key executives including CEO Harry Simeonidis and CFO Spiro Sakiris.
正如向美国证券交易委员会提交的新D表通知所示，Intelligent Bio Solutions Inc.已成功完成证券的豁免发行。此次发行于2024年3月12日结束，共筹集了10,100,683美元。该公司在特拉华州注册成立，从事医疗保健行业，特别是 “其他医疗保健” 类别，尚未透露其收入范围或总净资产价值。提供的证券包括股票和期权、认股权证或其他收购其他证券的权利。接受了外部投资者的最低投资额为10,000美元，共有8名投资者参与了此次发行。销售佣金总额为910,455美元，支付给拉登堡塔尔曼公司。Inc.，该公司还收到了普通股认股权证和报销费用。本次发行的收益不得用于向执行官、董事或发起人付款。Intelligent Bio Solutions的主要营业地点位于纽约州纽约，其主要高管包括首席执行官哈里·西蒙尼迪斯和首席财务官斯皮罗·萨基里斯。
正如向美国证券交易委员会提交的新D表通知所示，Intelligent Bio Solutions Inc.已成功完成证券的豁免发行。此次发行于2024年3月12日结束，共筹集了10,100,683美元。该公司在特拉华州注册成立，从事医疗保健行业，特别是 “其他医疗保健” 类别，尚未透露其收入范围或总净资产价值。提供的证券包括股票和期权、认股权证或其他收购其他证券的权利。接受了外部投资者的最低投资额为10,000美元，共有8名投资者参与了此次发行。销售佣金总额为910,455美元，支付给拉登堡塔尔曼公司。Inc.，该公司还收到了普通股认股权证和报销费用。本次发行的收益不得用于向执行官、董事或发起人付款。Intelligent Bio Solutions的主要营业地点位于纽约州纽约，其主要高管包括首席执行官哈里·西蒙尼迪斯和首席财务官斯皮罗·萨基里斯。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息